 James Kovacs
Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| env Gene Products, Human Immunodeficiency Virus | 7 | 2019 | 15 | 1.290 |
Why?
| | HIV-1 | 7 | 2019 | 908 | 0.830 |
Why?
| | Protein Multimerization | 3 | 2014 | 205 | 0.820 |
Why?
| | Complement C3d | 4 | 2013 | 62 | 0.760 |
Why?
| | HIV Antibodies | 6 | 2019 | 61 | 0.680 |
Why?
| | Antibodies, Neutralizing | 6 | 2019 | 340 | 0.660 |
Why?
| | Receptors, Complement 3d | 3 | 2010 | 129 | 0.640 |
Why?
| | HIV Envelope Protein gp120 | 3 | 2019 | 55 | 0.510 |
Why?
| | Protein Folding | 2 | 2014 | 277 | 0.450 |
Why?
| | Oligopeptides | 3 | 2007 | 267 | 0.420 |
Why?
| | Models, Molecular | 4 | 2019 | 1599 | 0.410 |
Why?
| | Protein Conformation | 4 | 2009 | 938 | 0.400 |
Why?
| | Amino Acids | 4 | 2009 | 519 | 0.380 |
Why?
| | AIDS Vaccines | 3 | 2018 | 53 | 0.350 |
Why?
| | Receptors, IgE | 1 | 2010 | 43 | 0.310 |
Why?
| | Interferon-alpha | 1 | 2010 | 193 | 0.290 |
Why?
| | Protein Structure, Quaternary | 4 | 2014 | 116 | 0.280 |
Why?
| | Protein Structure, Secondary | 2 | 2007 | 371 | 0.230 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2009 | 592 | 0.220 |
Why?
| | Guinea Pigs | 5 | 2019 | 159 | 0.210 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 4 | 2009 | 192 | 0.190 |
Why?
| | Epitopes | 4 | 2019 | 473 | 0.190 |
Why?
| | Masks | 1 | 2022 | 70 | 0.180 |
Why?
| | Peptides | 4 | 2009 | 1000 | 0.170 |
Why?
| | Complement Factor H | 1 | 2022 | 79 | 0.170 |
Why?
| | Protein Binding | 6 | 2019 | 2240 | 0.160 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 849 | 0.160 |
Why?
| | Vaccination | 4 | 2019 | 1428 | 0.150 |
Why?
| | Kidney Diseases | 1 | 2022 | 426 | 0.140 |
Why?
| | Binding Sites | 3 | 2010 | 1311 | 0.130 |
Why?
| | Ligands | 2 | 2010 | 668 | 0.130 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2010 | 347 | 0.130 |
Why?
| | HIV Envelope Protein gp160 | 1 | 2015 | 4 | 0.110 |
Why?
| | Complement Activation | 2 | 2022 | 399 | 0.110 |
Why?
| | HIV Envelope Protein gp41 | 1 | 2015 | 11 | 0.110 |
Why?
| | Surface Plasmon Resonance | 2 | 2013 | 87 | 0.110 |
Why?
| | Cricetulus | 1 | 2014 | 118 | 0.110 |
Why?
| | CHO Cells | 1 | 2014 | 169 | 0.110 |
Why?
| | Nanocapsules | 1 | 2014 | 14 | 0.100 |
Why?
| | Cricetinae | 1 | 2014 | 305 | 0.100 |
Why?
| | Vaccines | 1 | 2019 | 389 | 0.100 |
Why?
| | HIV | 1 | 2014 | 251 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 95 | 0.090 |
Why?
| | Amino Acid Sequence | 4 | 2019 | 2131 | 0.090 |
Why?
| | Animals | 11 | 2022 | 38106 | 0.090 |
Why?
| | Neutralization Tests | 1 | 2012 | 76 | 0.090 |
Why?
| | Ultracentrifugation | 1 | 2012 | 50 | 0.090 |
Why?
| | Chromatography, Gel | 1 | 2012 | 130 | 0.090 |
Why?
| | Lipids | 1 | 2014 | 707 | 0.070 |
Why?
| | Titrimetry | 1 | 2009 | 12 | 0.070 |
Why?
| | Recombinant Proteins | 4 | 2014 | 1368 | 0.070 |
Why?
| | Adaptive Immunity | 1 | 2010 | 167 | 0.070 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2009 | 532 | 0.070 |
Why?
| | Stereoisomerism | 1 | 2006 | 103 | 0.060 |
Why?
| | Circular Dichroism | 1 | 2006 | 151 | 0.060 |
Why?
| | Buffers | 1 | 2006 | 56 | 0.060 |
Why?
| | Salts | 1 | 2006 | 35 | 0.060 |
Why?
| | HIV Infections | 2 | 2019 | 3195 | 0.060 |
Why?
| | B-Lymphocytes | 1 | 2010 | 872 | 0.050 |
Why?
| | Humans | 9 | 2022 | 145785 | 0.050 |
Why?
| | CD4 Antigens | 2 | 2015 | 137 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2010 | 835 | 0.050 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 58 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1568 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 134 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2022 | 314 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2019 | 91 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 92 | 0.030 |
Why?
| | Antibody Formation | 1 | 2019 | 288 | 0.030 |
Why?
| | Immunization | 1 | 2019 | 375 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 741 | 0.030 |
Why?
| | Mice | 3 | 2022 | 18358 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2019 | 697 | 0.030 |
Why?
| | Virion | 1 | 2015 | 108 | 0.030 |
Why?
| | Cytoplasm | 1 | 2015 | 254 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1497 | 0.030 |
Why?
| | Molecular Weight | 1 | 2014 | 312 | 0.030 |
Why?
| | Antigens, Viral | 1 | 2014 | 182 | 0.020 |
Why?
| | Antigens | 1 | 2015 | 348 | 0.020 |
Why?
| | Immunity, Humoral | 1 | 2014 | 118 | 0.020 |
Why?
| | Complement C3-C5 Convertases | 1 | 2013 | 21 | 0.020 |
Why?
| | Drug Carriers | 1 | 2014 | 136 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 855 | 0.020 |
Why?
| | Choroidal Neovascularization | 1 | 2013 | 56 | 0.020 |
Why?
| | Spleen | 1 | 2013 | 508 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2968 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 105 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 8078 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2010 | 376 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 302 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 486 | 0.020 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2009 | 27 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 265 | 0.020 |
Why?
| | Female | 4 | 2019 | 79045 | 0.020 |
Why?
| | Amides | 1 | 2009 | 101 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4568 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 4090 | 0.020 |
Why?
| | Electrophoresis, Capillary | 1 | 2007 | 20 | 0.020 |
Why?
| | Chromatography, Ion Exchange | 1 | 2007 | 57 | 0.020 |
Why?
| | Molecular Biology | 1 | 2007 | 58 | 0.020 |
Why?
| | Drug Stability | 1 | 2007 | 169 | 0.010 |
Why?
| | Reference Standards | 1 | 2007 | 177 | 0.010 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2007 | 81 | 0.010 |
Why?
| | Temperature | 1 | 2007 | 633 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2006 | 732 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2883 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5995 | 0.010 |
Why?
| | Biomarkers | 1 | 2013 | 4302 | 0.010 |
Why?
| | Inflammation | 1 | 2013 | 2885 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 11794 | 0.010 |
Why?
|
|
Kovacs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|